iBio, Inc. (IBIO) Supply Chain: Key Partners, Risks, and Strategic Dependencies

Q: What is the Customer Analysis for IBIO?

iBio’s customer base is also concentrated, with Alnylam Pharmaceuticals (ALNY), Bristol-Myers Squibb (BMY), and Twist Bioscience (TWST) appearing multiple times. These firms are major players in the biotechnology and pharmaceutical sectors, suggesting that iBio’s products may be targeted toward high-value, specialized applications. However, the repeated presence of these firms also indicates a lack of diversification in customer relationships, which could increase vulnerability to shifts in dema

Q: What is the Supply Chain Risks for IBIO?

iBio’s supply chain is characterized by single-source dependencies and a lack of diversification, both in suppliers and customers. For example, the SEC filing evidence states: "Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and therapies for many of the diseases and conditions addressed by the product candidates our partners and collaborators may be developing or manufacturing or in

iBio, Inc. has 14 key suppliers and 14 major customers identified from SEC filings. Supply chain intelligence sourced from ChainSifter.

Executive Summary

iBio, Inc. (IBIO) operates in a highly concentrated and interdependent supply chain, with key relationships across both suppliers and customers in the biotechnology and pharmaceutical sectors. The most critical supplier, RUBRYC, is confirmed in SEC filings, while others like Alnylam Pharmaceuticals (ALNY) and Bristol-Myers Squibb (BMY) appear repeatedly but with lower confidence. This concentration, combined with overlapping supplier-customer relationships, suggests a high dependency on a limited set of industry players, which may pose risks to revenue stability and growth.

Supplier Analysis

iBio’s supply chain is composed of 14 suppliers, with varying levels of confidence in their relationships. The most confirmed supplier is RUBRYC with a confidence score of 0.92, based on a documented Stock Purchase Agreement. This relationship is significant, as RUBRYC appears to be a direct financial stakeholder, which may influence strategic alignment and long-term collaboration. However, the rest of the suppliers—such as Alnylam Pharmaceuticals (ALNY), Bristol-Myers Squibb (BMY), Twist Bioscience (TWST), and others—have a confidence score of 0.72, indicating inferred relationships rather than confirmed contracts.

RUBRYC is the only supplier with high confidence (0.92), suggesting a direct and significant relationship. This may indicate a strategic investment or partnership that could influence iBio’s product development and financial positioning.
Alnylam Pharmaceuticals (ALNY), Bristol-Myers Squibb (BMY), and Twist Bioscience (TWST) are repeated across the list, suggesting a potential overlap in collaboration or competition. Their presence multiple times may indicate a reliance on these firms for various aspects of development and manufacturing.
The low confidence score for most suppliers raises concerns about concentration risk. If iBio depends heavily on a small number of firms for critical operations, any disruption or competitive pressure from these entities could negatively impact iBio’s supply chain and innovation pipeline.

Customer Analysis

iBio’s customer base is also concentrated, with Alnylam Pharmaceuticals (ALNY), Bristol-Myers Squibb (BMY), and Twist Bioscience (TWST) appearing multiple times. These firms are major players in the biotechnology and pharmaceutical sectors, suggesting that iBio’s products may be targeted toward high-value, specialized applications. However, the repeated presence of these firms also indicates a lack of diversification in customer relationships, which could increase vulnerability to shifts in demand or pricing power from these entities.

Alnylam Pharmaceuticals (ALNY) appears twice in the customer list, which may indicate a strong or ongoing partnership. However, with a confidence score of 0.72, this relationship is inferred and not confirmed in filings, which introduces uncertainty about the sustainability of this revenue source.
The presence of Johnson & Johnson (JNJ) and Merck & Co. (MRK) suggests that iBio is operating within a high-stakes, high-revenue sector. However, the lack of confirmed contracts with these firms implies that iBio may not have long-term or exclusive agreements, which could limit its pricing power and revenue predictability.
The overall concentration of customers—especially among large pharmaceutical firms—signals that iBio may be in a position of limited pricing power, as it may need to compete with other suppliers to retain these clients.

Supply Chain Risks

iBio’s supply chain is characterized by single-source dependencies and a lack of diversification, both in suppliers and customers. For example, the SEC filing evidence states: "Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and therapies for many of the diseases and conditions addressed by the product candidates our partners and collaborators may be developing or manufacturing or in our own pipeline." This highlights the risk of competition with customers, which could lead to revenue erosion or loss of market share.

The repeated presence of firms like Alnylam Pharmaceuticals and Bristol-Myers Squibb as both suppliers and customers introduces the risk of conflict of interest or competition, which could lead to reduced collaboration or pricing pressures.
There is no evidence of geographic diversification in the supply chain, which could expose iBio to geographic risks such as regulatory changes, trade restrictions, or supply chain disruptions.
The lack of confirmed contracts with most suppliers and customers raises uncertainty about long-term revenue stability and the ability to scale operations.

Investor Takeaways

iBio’s supply chain is highly concentrated and interdependent, with significant reliance on a small number of firms in the biotechnology and pharmaceutical sectors. This structure may limit revenue stability and margin growth, as the company is vulnerable to shifts in customer demand, competitive pressures, and supply chain disruptions. The lack of confirmed contracts with most suppliers and customers introduces uncertainty about long-term profitability and scalability. Investors should closely monitor diversification efforts, contractual agreements, and geographic expansion to assess the company’s ability to mitigate these risks and achieve sustainable growth.